{
  "id": 9749,
  "url": "https://doi.org/10.3390/ph18010047",
  "title": "Harnessing the AI/ML in Drug and Biological Products Discovery and Development: The Regulatory Perspective",
  "summary": "Artificial Intelligence (AI) has the disruptive potential to transform patients' lives via innovations in pharmaceutical sciences, drug development, clinical trials, and manufacturing. However, it presents significant challenges, ethical concerns, and risks across sectors and societies. AI's rapid advancement has revealed regulatory gaps as existing public policies struggle to keep pace with the challenges posed by these emerging technologies. The term AI itself has become commonplace to argue t",
  "authors": "Fahimeh Mirakhori, Sarfaraz K. Niazi",
  "category": "research",
  "topics": "regulation,healthcare,biotech",
  "orgs": null,
  "regions": null,
  "published_at": "2025-01-03T00:00:00.000Z",
  "fetched_at": "2026-07-14T16:34:00.821Z",
  "source_slug": "openalex",
  "source_name": "OpenAlex",
  "source_homepage": "https://openalex.org",
  "ethics_ai_record_url": "https://ethics.ai/record/9749",
  "original_url": "https://doi.org/10.3390/ph18010047",
  "evidence_status": "source-only",
  "attribution": "via ethics.ai"
}